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8 mm thick) of the ventral portion of the left lateral liver lobe were collected and fixed in 10% neutral buffered formalin.
Anticoagulation and PMN depletion. Inhibition of coagulation system activation was achieved by administration of heparin. Rats were treated with LPS/RAN as above, but 1 h before RAN treatment, heparin (3000 U/kg, s.c.) or sterile saline was administered. Rats were killed 3 or 6 h after RAN administration, and serum and liver samples were taken. PMN depletion was accomplished by administration of a PMN antiserum before treatment with LPS/RAN. Rats were given 0.25 ml of either normal rabbit serum (normal serum) or rabbit anti-rat PMN serum (anti-PMN serum, Inter-cell Technologies, Jupiter, Fl) diluted 1:1
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unaware of treatment. Serum CINC-1 concentration was evaluated using a commercially available ELISA (Assay Designs, Inc., Ann Arbor, MI).
Evaluation of coagulation system activation. Plasma fibrinogen was determined from thrombin clotting time of diluted samples using a fibrometer and a commercially available kit (B4233) from Dade-Behring Inc. (Deerfield, IL). Plasma thrombin-antithrombin (TAT) concentration was determined by ELISA using kit #OWMG15 from Dade-Behring.
HPC isolation. HPCs were isolated using the Gibco HPC Product Line (Invitrogen, Carlsbad, CA) including liver perfusion medium, liver digest medium, and HPC wash buffer (Cat. Nos 17701, 17703, 17704) . All reagents were warmed to 37 °C before perfusion. Rats were anesthetized with sodium pentobarbital (50 mg/kg, ip), and the portal vein was cannulated. The liver was initially perfused with 150 ml perfusion medium at a rate of 12 ml/min, with excess medium draining from the severed vena cava. This was followed immediately by perfusion with 100 ml of liver digestion medium at a rate of 12 ml/min. The liver was transferred carefully to a culture dish containing HPC wash medium and gently scraped to separate cells. The resulting liver digest was passed through sterile gauze and spun briefly at 50xg to pellet HPCs. The resulting pellet was washed two times with 50 ml volumes of HPC wash medium. HPCs were then resuspended at a density of 2.5 X 10 5 cells/ml in Williams' Medium E (Invitrogen, Carlsbad, CA) containing 5% Cosmic Calf Serum (CCS, Atlanta Biologicals, Norcross, GA) and plated in 12-well cell culture plates (Fisher Scientific Co., Pittsburgh, PA) at 0.80 ml/well. Cells were allowed to attach for 2-3 h before treatment.
Effect of hypoxia on elastase-induced cytotoxicity. Serum-containing medium was removed, and fresh Williams' Medium E containing various concentrations of human PMN elastase (Molecular Innovations, Southfield, MI) were added to HPCs. PMN elastase activity This article has not been copyedited and formatted. The final version may differ from this version. was determined using the colorometric PMN elastase substrate, MeOSuc-Ala-Ala-Pro-Val-pNA (Calbiochem, San Diego, CA). One unit of PMN elastase activity was defined as the amount of enzyme required to cause a change of absorbance of 1.0 at 410 nm in 10 min at 37° C. PMN elastase-treated cells were immediately transferred to incubators containing either 20% or 5% O 2 , with CO 2 controlled at 5%. Two or 8 h later, the medium was collected, and the remaining attached cells were lysed with an equal volume of 1% triton X-100. Media and lysates were centrifuged at 600xg for 5 min. Cytotoxicity was assessed by measuring ALT release into the medium using Infinity-ALT reagent from Thermo Electron Corp. (Louisville, CO). ALT activity in the medium was expressed as a percent of total ALT activity (i.e., medium activity plus lysate activity). Treatment with RAN alone caused a modest (~8-fold) but statistically significant increase in serum CINC-1 (Fig. 1A) . By contrast, rats treated with either LPS alone or LPS/RAN had a large increase (~700-fold) in serum CINC-1 (Fig. 1A) . PMN accumulation occurred in livers of rats treated with LPS; the degree of accumulation was slightly less in rats cotreated with RAN ( Fig.   1B ). The distribution of PMNs was panlobular in rats given either LPS/Veh or LPS/RAN, with occasional clusters of PMNs in midzonal areas of necrosis in LPS/RAN-treated rats (Fig 1C and   D) .
Statistical analysis.
Effect of PMN depletion on LPS/RAN-induced liver injury. Although LPS/RAN
administration is hepatotoxic, given alone the doses of LPS and RAN are not hepatotoxic within 24 h after administration (Luyendyk et al., 2003b) . LPS/RAN-treated rats were pretreated with either normal serum or anti-PMN serum and were killed 6 h after RAN administration (i.e., time of peak injury; Luyendyk et al., 2003b) to determine the role of PMNs in the liver injury.
LPS/RAN-treatment caused a pronounced neutrophilia (Table 1) (Table 2 ). In contrast, a slight but significant increase in accumulated band cells (immature PMNs) occurred in anti-PMN serum/LPS/RANtreated rats compared to those animals given normal serum (Table 2) .
A significant increase in serum ALT activity was observed in normal serum/LPS/RANtreated rats at 6 h, and this was markedly reduced (~80%) by anti-PMN serum pretreatment (Fig.   2D ). Distribution of PMNs was panlobular in LPS/RAN-treated rats given either normal serum or anti-PMN serum. However, clustering of PMNs, many of which were categorized as degenerate, occurred in midzonal and subserosal areas of oncotic necrosis in normal serum/LPS/RAN-treated rats ( Fig. 2A) . Consistent with the decrease in serum ALT activity, the frequency and size of lesions in LPS/RAN-treated rats was markedly reduced by anti-PMN serum pretreatment (Fig. 2B) .
Effect of PMN depletion on coagulation system activation after LPS/RAN treatment. Coagulation system activation was estimated in LPS/RAN-treated rats given either (Fig. 3A) . Plasma TAT concentration increased after LPS/RAN-treatment and was not significantly reduced by anti-PMN serum administration (Fig.   3B ).
Effect of heparin on hepatotoxicity after LPS/RAN treatment. LPS/RAN-treatment caused a significant increase in serum ALT activity that was modest at 3 h and progressed through 6 h after RAN administration (Fig. 4A ). Lesions in livers of LPS/RAN-treated rats have been described previously (Luyendyk et al., 2003b) and were characterized by midzonal and subserosal hepatocellular oncotic necrosis and neutrophilic infiltrate (data not shown). Previous studies showed that the coagulation system is a critical mediator of LPS/RAN-induced liver injury (Luyendyk et al., 2004a) . Confirming these results, serum ALT activity was significantly attenuated by heparin at 6 h ( Fig. 4A) , a time associated with maximal injury in LPS/RANtreated rats (Luyendyk et al., 2003b) . Furthermore, heparin prevented the slight increase in ALT activity at 3 h observed in this study ( occurred to a similar degree in LPS-treated rats, irrespective of RAN administration (Fig. 1A) .
Consistent with CINC-1 gene expression in this model (Luyendyk et al., 2004b; D11445exon#1-4_s_at) , serum CINC-1 concentration was increased in LPS/Veh and LPS/RAN-treated rats to a similar degree. This suggests that increased CINC-1 is not sufficient to cause liver injury. In addition to its effect on accumulation of PMNs in liver, LPS/RAN-cotreatment caused a decrease in blood lymphocytes and an increase in blood PMNs in the absence of a change in total leukocyte count (Table 1) . Similar changes in blood leukocyte concentration were observed in rats treated with a large, hepatotoxic dose of LPS (Hewett et al., 1992) . These results suggest that the effect of LPS/RAN-treatment on circulating and hepatic PMNs is driven largely by LPS.
Liver injury in this model depends on an activated hemostatic system and the formation of fibrin clots (Luyendyk et al., 2004a) . Confirming this result, heparin administration prevented or delayed hepatic fibrin deposition and hepatocellular injury in LPS/RAN-treated rats (Fig 4) . In another model of liver damage involving hypoxia (i.e., ischemia-reperfusion), coagulation system activation favors chemokine production and PMN accumulation (Yamaguchi et al., 1997) . Inasmuch as hemostasis-mediated hepatocellular hypoxia occurs in LPS/RAN-treated rats, we considered the possibility that coagulation system activation is important for the production of CINC-1 and liver PMN accumulation. This possibility seems unlikely, since as opposed to each contributing independently to liver damage. One possibility is that PMNs contribute to LPS/RAN-induced liver injury by participating in coagulation system activation.
PMN depletion was without effect on LPS/RAN-induced changes in plasma biomarkers of coagulation system activation (Fig. 3) , suggesting that PMNs do not play a major role in coagulation in this model; However, we cannot rule out the possibility that liver specific effects might not be reflected in systemic markers of coagulation system activation. Another possibility is that an activated coagulation system is required for full activation of PMNs in LPS/RANtreated rats. This could occur in several ways. Values for Veh/Veh/Veh-treated rats were too small to be apparent in (B). (Fig. 1 ) but at the dose used did not cause hepatocellular injury (Luyendyk et al., 2003b) . In LPS/RAN-treated rats, hepatocellular injury was dependent on PMNs (Fig. 2) , suggesting that RAN contributes to PMN activation and release of cytotoxic factors including proteases (e.g., elastase). Depletion of PMNs was without effect on coagulation system activation ( Fig. 3 ) and anticoagulation did not influence hepatic PMN accumulation (Fig. 5) , suggesting that PMN accumulation/activation and coagulation system activation occur independently. In vitro, hypoxia rendered hepatocytes (HPCs) sensitive to killing by PMN elastase (Fig. 7) , suggesting liver hypoxia (e.g., caused by fibrin deposition) increases susceptibility to PMN elastase -induced hepatocellular injury.
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